In Its Second Biotech Deal In Three Months, Ranbaxy Signs Pact With Pfenex For An Undisclosed Biosimilar
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - Moving one step closer to realizing its ambitions in the fast-emerging biosimilars space, Daiichi Sankyo's Indian arm Ranbaxy signed a development deal with the San Diego-based Pfenex, a spin-off of the Dow Chemical Company
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).